Turning briefly to our hepatitis B program ... that's in their label right now. So we are aiming for a chronic viral suppressive regimen. We think we can suppress the virus in the vast majority ...

Viral hepatitis is a leading cause of liver disease, liver cancer and liver transplant in the United States and is a focus of an annual national awareness campaign that occurs ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. The three main types—Hepatitis A, B, ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

The diagnosis of hepatitis A virus (HAV) infection is based on the detection of anti-HAV IgM. Shortcomings of this serological approach include the persistence of IgM after normalization of liver ...

May 7, 2025 — Influenza viruses are among the most likely triggers of future pandemics. A research team has developed a method that can be used to study the ... Shingles Vaccine Lowers the Risk ...

Senior Fellow and Chief Economist at IPA Adam Creighton discusses Independent MP Zoe Daniel’s “justified” and “embarrassing” electorate seat loss. “I don’t understand why we’re ...